. Author manuscript; available in PMC: 2022 May 1.

Published in final edited form as: Cancer Cytopathol. 2020 Dec 28;129(5):394–404. doi: 10.1002/cncy.22399

TABLE 4.

Comparison of Studies That Investigated the Use of p16 Immunohistochemistry in Cytology Specimens

	No. of Cases	Cytologic Preparation	Tumor Cellularity	Clusters/Single Cells Scored	Positivity Criteria	Reference Test	P16 Performance
	No. of Cases	Cytologic Preparation	Tumor Cellularity	Clusters/Single Cells Scored	Positivity Criteria	Reference Test	Sensitivity (%)	Specificity (%)
Begum 2007³¹	77	CB	Any	Both	Any staining	HPV16-ISH in cytology specimens	92	94
Jannapureddy 2010³⁴	40	CB	Adequate material, NOS	Both	Any nuclear and cytoplasmic staining	HPV-ISH in cytology specimens	100	77
Jakscha 2013³⁰	25	Smears	Adequate material, NOS	Both	Strong cytoplasmic staining in ≥5% of tumor cells	P16 IHC in surgical specimens	88	100
Jalaly 2015²⁹	48	CB	Any	Clusters only	Strong staining in ≥15% of tumor cells	P16 IHC in surgical specimens	97	100
Jalaly 2015²⁹	48	CB	Any	Clusters only	Strong staining in ≥15% of tumor cells	HPV-ISH in cytology specimens	90	100
Xu 2016²³	60	CB, smear, ThinPrep slide	Any	Both	Moderate-strong staining in ≥1 % of tumor cells	P16 IHC in surgical specimens	95	100
Xu 2016²³	60	CB, smear, ThinPrep slide	Any	Both	Moderate-strong staining in ≥10% of tumor cells	HPV-ISH in cytology specimens	94	75
Hou 2016³³	73	CB	At least 100 cells	Both	Strong nuclear and cytoplasmic staining in ≥70% of tumor cells	HPV-ISH in cytology specimens	98	52
Wong 2019³²	97	CB	Any	Both	Any staining	HPV-ISH/PCR in cytology CBs	93	92
Yang 2019²²	50	Smear	Not reported	Both	Weak nuclear and cytoplasmic staining ≥50% of tumor cells	P16 IHC in surgical specimens	74	100
Current study	42	CB	At least 10 cells	Clusters	Moderate nuclear and cytoplasmic staining in 40% of tumor cells (at least)	P16 IHC in surgical specimens	100	100

Abbreviations: CB, cellblock; HPV, human papillomavirus; IHC, immunohistochemistry; ISH, in situ hybridization.